Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- CONN -16.3%, MTL -8.6%, OLLI -5%, NG -1.5%
Other news:
- CNAT -28.3% (Conatus Pharma reports top-line results from ph 2b POLT-HCV-SVR clinical trial; trial did not meet its primary endpoint but biopsy-based proof of concept in liver fibrosis and cirrhosis supports further evaluation)
- CHEK -13.5% (files for $10 mln ordinary share offering)
- CPRX -8.7% (following yesterday's 16% move higher)
- NOG -6.3% (Northern Oil & Gas amended Exchange Agreement -- reduced minimum amount of Equity Raise to $140 mln while providing Common Stock in the Equity Raise be issued solely for cash)
- LFIN -4.8% (pulling back in after seeing notable move higher ahead of last night's CEO appearance on Fast Money)
- XOMA -3.7% (amends license agreement and purchase agreement with Rezolute)
- CLLS -3% (prices follow-on offering of 5,646,000 ADS's at $31.00 per ADS)
Analyst comments:
- JCI -1.7% (downgraded to Underperform from Sector Perform at RBC Capital Mkts)
- MU -1.4% (initiated with Sell rating at UBS)